Xenon Pharmaceuticals Inc.
XENE
Rang in aandelen
#4660
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Aandeelprijs
$33.60
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$3.25B
Verandering (1 dag)
-2.13%
Verandering (1 jaar)
-19.29%
Land
CA
Handel Xenon Pharmaceuticals Inc. (XENE)
Categorie
Healthcare
Operationele marge voor Xenon Pharmaceuticals Inc. (XENE)
Operationele marge op October 2026 TTM: 0.00%
Volgens de meest recente financiële rapporten en aandelenkoers van Xenon Pharmaceuticals Inc. is de huidige operationele marge (TTM) 0.00%. Eind 2023 had het bedrijf een operationele marge van 0.00%.
Geschiedenis van de operationele marge van Xenon Pharmaceuticals Inc. van 2011 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -1,368.91% | 219.50% |
| 2021 | -428.45% | 340.29% |
| 2020 | -97.31% | -84.48% |
| 2019 | -627.02% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -10,474.28% | 660.97% |
| 2016 | -1,376.43% | 2,190.23% |
| 2015 | -60.10% | -253.51% |
| 2014 | 39.15% | 10.28% |
| 2013 | 35.50% | -261.07% |
| 2012 | -22.04% | -87.41% |
| 2011 | -175.11% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.